Epigenetic modulation as a therapy in systemic sclerosis

O'Reilly, Steven (2019) Epigenetic modulation as a therapy in systemic sclerosis. Rheumatology, 58 (2). pp. 191-196. ISSN 1462-0324

Full text not available from this repository. (Request a copy)
Official URL: https://doi.org/10.1093/rheumatology/key071


SSc is an autoimmune idiopathic disease in which there is an inflammatory component driving fibrosis. The chief cell involved is the myofibroblast, which when activated secretes copious amounts of extracellular matrix that forms deposits, leading to stiffness and fibrosis. The fibrosis is most prevalent in the skin and lungs. In recent years epigenetic modifications have been uncovered that positively and negatively regulate the genesis of the myofibroblasts and that can be activated and regulated by a variety of cytokines and hormones. The epigenetic contribution to these cells and to SSc is only now really coming to light, and this opens up a new therapeutic target for the disease for which many epigenetic drugs, such as miRNA replacements, are beginning to be developed. This review will examine the epigenetic regulators in the disease and possible targeting of these.

Item Type: Article
Uncontrolled Keywords: fibrosis, epigenetics, methylation, histones
Subjects: B200 Pharmacology, Toxicology and Pharmacy
Department: Faculties > Health and Life Sciences > Applied Sciences
Depositing User: Elena Carlaw
Date Deposited: 07 Mar 2019 13:51
Last Modified: 10 Oct 2019 21:46
URI: http://nrl.northumbria.ac.uk/id/eprint/38336

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics